Aarti Drugs Limited
1,691words
2turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
Rs. 100
crore
Rs.
2,700
Rs. 2,000
Rs.
200
Rs. 200
Rs. 1,000 crore
100%
Rs. 100 crore
4,261
MT
38%
1 MT
Speaking time
1
1
Advertisement
Opening remarks
Captive consumption
Rs. 300 crores Revenue Growth Higher Margins Higher RoCE 10 11 Financial Highlights of FY23 and Q1FY24 FY 23 Result Highlights Rs. crores Revenue EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) 13.7% 11.3% 8.2% 6.1% +9% 2,718 2,500 341 308 205 166 FY22 FY23 FY22 FY23 FY22 FY23 1. EBITDA includes other income & excludes exceptional items 13 Q1 FY24 Result Highlights Rs. crores Revenue EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) +6.3% 742 622 661 10.8% 12.7% 12.8% 5.6% 7.6% 7.3% 94 85 67 56 48 35 Q1 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q4 FY23 Q1 FY24 1. EBITDA includes other income & excludes exceptional items 14 FY22 Segmental Break-up FY22 FY23 80% 11% 4% 5% 82% 10% 5% 3% API Formulation API Formulation Speciality Chemicals Intermediates & Others Speciality Chemicals Intermediates & Others 15 16 Historical Performance At A Glance Strong Financial Performance Revenue (Rs. Crores) EBITDA (Rs. Crores) PAT (Rs. Crores) Consolidat ed 2,718 2,500 2,159 1,808 1,563 442 28
Advertisement